Yahoo
    Copenhagen - Delayed Quote DKK

    Zealand Pharma A/S (ZEAL.CO)

    234.20 +2.70 (+1.17%)
    At close: November 3 at 4:59:55 PM GMT+1
    Loading Chart for ZEAL.CO
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

    Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
    GlobeNewswire 16d ago
    Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings?

    Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings?
    Simply Wall St. 25d ago
    Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success

    Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success
    Simply Wall St. 25d ago
    Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes

    Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes
    Simply Wall St. 25d ago
    Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

    Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
    GlobeNewswire 27d ago
    Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

    Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
    GlobeNewswire 29d ago
    Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial

    Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial
    PREMIUM
    MT Newswires 1mo ago
    Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

    Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
    GlobeNewswire 1mo ago
    Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

    Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
    GlobeNewswire 1mo ago
    Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

    Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
    GlobeNewswire 1mo ago
    Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

    Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
    GlobeNewswire 1mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: